JPWO2020179859A1 - - Google Patents

Info

Publication number
JPWO2020179859A1
JPWO2020179859A1 JP2021503643A JP2021503643A JPWO2020179859A1 JP WO2020179859 A1 JPWO2020179859 A1 JP WO2020179859A1 JP 2021503643 A JP2021503643 A JP 2021503643A JP 2021503643 A JP2021503643 A JP 2021503643A JP WO2020179859 A1 JPWO2020179859 A1 JP WO2020179859A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021503643A
Other languages
Japanese (ja)
Other versions
JP7413346B2 (ja
JPWO2020179859A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020179859A1 publication Critical patent/JPWO2020179859A1/ja
Publication of JPWO2020179859A5 publication Critical patent/JPWO2020179859A5/ja
Application granted granted Critical
Publication of JP7413346B2 publication Critical patent/JP7413346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021503643A 2019-03-06 2020-03-05 ピロロピラゾール誘導体 Active JP7413346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019040649 2019-03-06
JP2019040649 2019-03-06
PCT/JP2020/009357 WO2020179859A1 (ja) 2019-03-06 2020-03-05 ピロロピラゾール誘導体

Publications (3)

Publication Number Publication Date
JPWO2020179859A1 true JPWO2020179859A1 (https=) 2020-09-10
JPWO2020179859A5 JPWO2020179859A5 (https=) 2022-11-11
JP7413346B2 JP7413346B2 (ja) 2024-01-15

Family

ID=72338358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503643A Active JP7413346B2 (ja) 2019-03-06 2020-03-05 ピロロピラゾール誘導体

Country Status (7)

Country Link
US (1) US12240855B2 (https=)
EP (1) EP3936192B1 (https=)
JP (1) JP7413346B2 (https=)
KR (1) KR20210135521A (https=)
CN (1) CN113543852A (https=)
TW (1) TW202100526A (https=)
WO (1) WO2020179859A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080305A1 (ja) * 2020-10-13 2022-04-21 第一三共株式会社 抗ｐｔｄｓｓ２抗体
CN114426466B (zh) * 2020-10-29 2023-11-21 江苏和成新材料有限公司 一种醇羟基供体与活性氢供体进行光延反应的方法
US12350241B1 (en) 2024-04-29 2025-07-08 Imam Mohammad Ibn Saud Islamic University Method for inhibiting proliferation of cancer cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046030A2 (en) * 2010-10-07 2012-04-12 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
CN104876936A (zh) * 2015-05-25 2015-09-02 中国人民解放军第二军医大学 吡咯酮并吡唑类化合物的制备及作为药物的用途
WO2016148115A1 (ja) * 2015-03-16 2016-09-22 第一三共株式会社 ホスファチジルセリンシンターゼ１阻害剤への応答性を予測する方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0395144A (ja) 1989-08-04 1991-04-19 Ono Pharmaceut Co Ltd アミノフェノール誘導体の製造方法
JPH1129540A (ja) 1997-07-04 1999-02-02 Showa Kako Kk エステル誘導体の製造方法
WO1999048880A1 (en) 1998-03-23 1999-09-30 Asahi Kasei Kogyo Kabushiki Kaisha Benzothiazolone-7-sulfonamide derivatives
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
MXPA03001848A (es) 2000-08-31 2003-06-04 Pfizer Derivados de fenoxibencilamina como inhibidores de la reabsorcion de serotonina.
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
GB0109103D0 (en) 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
JP2003321406A (ja) 2002-04-30 2003-11-11 Mitsubishi Gas Chem Co Inc 高純度フルオロアルキルベンゼン誘導体及びその製造法
US20040132708A1 (en) 2002-05-01 2004-07-08 Wyeth Process for preparing 6-alkylidene penem derivatives
AU2003235447A1 (en) 2002-05-31 2003-12-19 Banyu Pharmaceutical Co., Ltd. Method of substituent introduction through halogen-metal exchange reaction
ES2339112T3 (es) 2002-08-21 2010-05-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
EP1537074B1 (en) 2002-09-04 2019-02-27 Merck Canada Inc. Cathepsin cysteine protease inhibitors
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
TW200615273A (en) 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
JP4794873B2 (ja) 2005-03-03 2011-10-19 富士フイルムファインケミカルズ株式会社 ハロゲン−リチウム交換反応を用いる有機化合物の製造法
KR20080002832A (ko) 2005-03-16 2008-01-04 얀센 파마슈티카 엔.브이. 보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
TW200716104A (en) 2005-06-01 2007-05-01 Wyeth Corp Tricyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
EP1893588A1 (en) 2005-06-10 2008-03-05 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2009502783A (ja) 2005-07-20 2009-01-29 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性オキサゾリジンジオン及びチアゾリジンジオン
CA2619881A1 (en) 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
WO2007047397A2 (en) 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
CA2637312A1 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007140005A2 (en) 2006-05-26 2007-12-06 Janssen Pharmaceutica N.V. Oxazolyl piperidine modulators of fatty acid amide hydrolase
ATE520651T1 (de) 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
WO2008072726A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体
TW200843739A (en) 2007-03-30 2008-11-16 Shionogi & Co Novel pyrrolinone derivative and composition containing the same
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
WO2009058921A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2009120553A (ja) 2007-11-16 2009-06-04 Taisho Pharmaceutical Co Ltd Ｃ−フェニルグルシト−ル化合物を有効成分とする糖尿病治療剤
CN101932577B (zh) 2007-11-30 2013-07-17 拜耳知识产权有限责任公司 杂芳基取代的哌啶
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
JP2009155212A (ja) 2007-12-25 2009-07-16 Taisho Pharmaceutical Co Ltd Ｃ−フェニル１−チオグルシト−ル化合物を有効成分とする糖尿病治療剤
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP2254415B1 (en) 2008-02-19 2013-01-23 Janssen Pharmaceutica, N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2272817A4 (en) 2008-04-11 2011-12-14 Inst Med Molecular Design Inc PAI-1 INHIBITORS
US20110053949A1 (en) 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
WO2009129625A1 (en) 2008-04-22 2009-10-29 Merck Frosst Canada Ltd. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
MX2010012492A (es) 2008-05-27 2010-12-21 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
AU2009252615B2 (en) 2008-05-29 2013-08-15 Kowa Company, Ltd. Substituted carbinol compound having cyclic linker
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
EP2318410A2 (en) 2008-07-09 2011-05-11 Envivo Pharmaceuticals, Inc. New small-molecule pde-10 inhibitors
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
TW201016702A (en) 2008-09-25 2010-05-01 Shionogi & Co Novel pyrrolinone derivative and pharmaceutical composition comprising the same
WO2010123599A2 (en) 2009-01-23 2010-10-28 The Board Of Trustees Of The University Of Illinois Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
PE20120578A1 (es) 2009-02-10 2012-06-17 Abbott Lab Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
CN103249721B (zh) 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
BR112013009828A2 (pt) 2010-10-22 2016-07-26 Janssen Pharmaceutica Nv diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase
TWI396678B (zh) 2010-12-07 2013-05-21 Nat Univ Tsing Hua 二級醇製備方法
WO2012093174A1 (en) 2011-01-07 2012-07-12 Vivalis 1-(6-membered azo-heterocyclic)-2,5-dihydro-1h-pyrrol-2-one derivatives as anti-hepatitis c virus, the pharmaceutical composition thereof and their therapeutic use
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
FR2973487B1 (fr) 2011-03-31 2018-01-26 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Procede et appareil de production d'un gaz de l'air sous pression par distillation cryogenique
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
EP2520556A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Radiolabeled amino acids for diagnostic imaging
GB201113689D0 (en) 2011-08-09 2011-09-21 Amakem Nv Novel PDE4 inhibitors
AR087875A1 (es) 2011-09-16 2014-04-23 Actelion Pharmaceuticals Ltd Proceso para la elaboracion de derivados de piridazina como intermediarios de sintesis de antibioticos
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
MX360323B (es) 2012-04-25 2018-10-29 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de ttx-s.
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
TWI583670B (zh) 2012-07-30 2017-05-21 大正製藥股份有限公司 Partially saturated nitrogenous heterocyclic compounds
ES2661585T3 (es) 2012-10-31 2018-04-02 Raqualia Pharma Inc Derivados de pirazolopiridina como bloqueadores de TTX-S
JP2016028016A (ja) 2012-12-12 2016-02-25 大日本住友製薬株式会社 オキサジアゾール誘導体とその医薬用途
US9834521B2 (en) 2013-03-15 2017-12-05 Ariad Pharmaceuticals, Inc. Choline kinase inhibitors
KR102214222B1 (ko) 2013-07-10 2021-02-08 메이지 세이카 파루마 가부시키가이샤 신규 pde4 저해제
EP2905282A1 (en) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
AP2016009465A0 (en) 2014-04-01 2016-09-30 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
WO2015160665A1 (en) 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
WO2016019588A1 (en) 2014-08-08 2016-02-11 The Broad Institute, Inc. Oxacazone compounds to treat clostridium difficile
EP3204351A1 (en) 2014-10-08 2017-08-16 Dow Global Technologies LLC Method for coupling a fluorosulfonate compound with an amine compound
WO2016115282A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
EP3280709B1 (en) 2015-04-10 2021-05-26 FMC Corporation Substituted cyclic amides as herbicides
ES2735924T3 (es) 2015-04-17 2019-12-20 Dow Agrosciences Llc Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procesos, relacionados con ellas
WO2017069601A1 (en) 2015-10-19 2017-04-27 Latvian Institute Of Organic Synthesis Substituted aminoalkylazoles as malarial aspartic protease inhibitors
US11319299B2 (en) 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
EP3538523B1 (en) 2016-11-08 2021-05-19 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046030A2 (en) * 2010-10-07 2012-04-12 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
WO2016148115A1 (ja) * 2015-03-16 2016-09-22 第一三共株式会社 ホスファチジルセリンシンターゼ１阻害剤への応答性を予測する方法
CN104876936A (zh) * 2015-05-25 2015-09-02 中国人民解放军第二军医大学 吡咯酮并吡唑类化合物的制备及作为药物的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MANGIATORDI, G. F. ET AL.: "Novel chemotypes targeting tubulin at the colchicine binding site and unbiasing P-glycoprotein", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 139, JPN6020016114, 2017, pages 792 - 803, ISSN: 0005215321 *
ZHOU, D. ET AL.: "Small molecules inhibit ex vivo tumor growth in bone", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 26(23-24), JPN6020016111, 2018, pages 6128 - 6134, ISSN: 0005215320 *

Also Published As

Publication number Publication date
US12240855B2 (en) 2025-03-04
EP3936192A1 (en) 2022-01-12
US20220185815A1 (en) 2022-06-16
KR20210135521A (ko) 2021-11-15
TW202100526A (zh) 2021-01-01
JP7413346B2 (ja) 2024-01-15
EP3936192A4 (en) 2022-11-16
EP3936192B1 (en) 2025-04-09
WO2020179859A1 (ja) 2020-09-10
CN113543852A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
BR112021013944A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231227

R150 Certificate of patent or registration of utility model

Ref document number: 7413346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150